Search

Search Results

1. Lifetime risks of second primary malignancies after pediatric Hodgkin lymphoma and non-Hodgkin lymphoma

   Objectives

   Survivors after pediatric Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are with lifetime risk for second primary malignancy...

   Laduona Wang, Yue Zheng, ... Yijun Wu in Journal of Cancer Research and Clinical Oncology

   Article Open access 27 January 2024
   

2. Comparison of diffusion-weighted MRI and [¹⁸F]FDG PET/MRI for treatment monitoring in pediatric Hodgkin and non-Hodgkin lymphoma

   Objective

   To compare tumor therapy response assessments with whole-body diffusion-weighted imaging (WB-DWI) and 18F-fluorodeoxyglucose ([ ¹⁸ F]FDG)...

   Wipawee Morakote, Lucia Baratto, ... Heike E. Daldrup-Link in European Radiology

   Article 05 August 2023
   

3. Vogt-Koyanagi-Harada disease developed during chemotherapy for Hodgkin lymphoma: a case report

   Background

   Ocular manifestations are known for non-Hodgkin lymphoma, but are rare for Hodgkin lymphoma. We report a case of Vogt-Koyanagi-Harada (VKH)...

   Mutsumi Koyama, Euido Nishijima, ... Masaharu Akiyama in BMC Ophthalmology

   Article Open access 13 March 2024
   

4. Unusual Presentation of Non-Hodgkin Lymphoma of Two Cases: Case Report

   Lymphomas are a diverse group of neoplastic disorders arising primarily in lymph nodes. They have been majorly classified into Hodgkin and...

   Haritha S, Shyam Sudhakar Sudarsan, ... Sakthimurugan Sankar in Indian Journal of Otolaryngology and Head & Neck Surgery

   Article 26 April 2024
   

5. Aberrant synaptophysin expression in classic Hodgkin lymphoma

   Background

   Synaptophysin is an immunohistochemical marker for neuroendocrine differentiation and is widely used in pathologic diagnosis. Its...

   Soyoung Im, Jeong-A. Kim, ... Uiju Cho in Diagnostic Pathology

   Article Open access 18 November 2022
   

6. Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma

   Background

   The combination of rituximab and chemotherapy is a first-line treatment for patients with B-cell non-Hodgkin lymphoma. Lenalidomide is an...

   Yang Liu, Yanju Li, ... Feiqing Wang in Discover Oncology

   Article Open access 05 April 2024
   

7. Treatment patterns and outcomes for Hodgkin Lymphoma patients aged 60 and older: a report from the Brazilian Prospective Hodgkin Lymphoma Registry

   The treatment of older patients with Hodgkin lymphoma (HL) remains a challenge. We sought to identify the treatment patterns and outcomes in older HL...

   Lilian Goveia, Nelson Castro, ... Irene Biasoli in Annals of Hematology

   Article 21 July 2023
   

8. Prognostic significance of serum monoclonal proteins based on immunofixation electrophoresis in B-cell non-Hodgkin lymphoma

   The presence of serum monoclonal components has been associated with poor outcomes in various hematological malignancies. The current study focused...

   Yuyang Gao, **aoyan Feng, ... Mingzhi Zhang in Annals of Hematology

   Article 20 December 2023
   

9. Exposure–response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma

   Purpose

   To investigate camidanlumab tesirine (Cami) exposure–response (E–R) relationships, using an integrated population pharmacokinetic model, for...

   Marie Toukam, Joseph P. Boni, ... Jens Wuerthner in Cancer Chemotherapy and Pharmacology

   Article 04 November 2022
   

10. Epiregulin: A new prognostic molecule in non-Hodgkin lymphoma

    Background

    Epiregulin is a molecule that plays a role in cell proliferation, tumor development, inflammation, and angiogenesis in malignant diseases.

    ...

    Ismail Demir, Ozden Yildirim Akan, ... Oktay Bilgir in Irish Journal of Medical Science (1971 -)

    Article 25 January 2024
    

11. The spectrum of nodular lymphocyte predominant Hodgkin lymphoma: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology

    Session 4 of the 2021 European Association of Haematopathology/Society for Hematopathology Workshop focused on nodular lymphocyte predominant Hodgkin...

    Sylvia Hartmann, Stefan Dojcinov, ... Daphne de Jong in Virchows Archiv

    Article Open access 02 August 2023
    

12. Hodgkin lymphoma—how much therapy do we need?

    Over the past few decades, cure rates for Hodgkin’s lymphoma (HL) have consistently improved with advances in chemotherapy and radiation treatment....

    Barbara Lehner, Michael Panny in memo - Magazine of European Medical Oncology

    Article 12 December 2022

13. Relapsed nodular lymphocyte-predominant Hodgkin lymphoma presenting as severe paraneoplastic hepatitis: a case report

    Background

    Hematological malignancies are an infrequent but important cause of liver dysfunction. There are several mechanisms by which this can...

    Anthony J. Deacon, Naeman N. Goetz, ... Barbara Leggett in Journal of Medical Case Reports

    Article Open access 30 June 2023
    

14. Isolated gastric involvement of recurrent Hodgkin lymphoma: a case report and review of the literature

    Background

    Although the gastrointestinal tract is one of the most common sites for extranodal lymphoma, gastrointestinal lymphoma is a rare disease...

    Soroush Kohansal, Mohammad Ashouri, Narjes Mohammadzadeh in Journal of Medical Case Reports

    Article Open access 05 May 2023
    

15. A case of Hodgkin lymphoma-type Richter syndrome presenting as small-intestinal perforation

    Hodgkin lymphoma type of Richter syndrome (HL-type RS) is a rare disease that arises in patients with chronic lymphocytic leukemia (CLL). HL-type RS...

    Kosuke Miki, Reiki Ogasawara, ... Shuichi Ota in International Journal of Hematology

    Article 06 September 2023
    

16. Thrombocytopenia, anasarca, and renal insufficiency as severe and rare complications of Hodgkin lymphoma: a case report

    Background

    Patients with Hodgkin lymphoma exhibit various clinical presentations. Needle biopsy of the lymph nodes is a minimally invasive procedure...

    Tatsuya Kikuchi, Yoshinori Tanaka, ... Ryoichi Okamoto in Journal of Medical Case Reports

    Article Open access 21 February 2023
    

17. In silico study of polyphenols as potential inhibitors of MALT1 protein in non-Hodgkin lymphoma

    Non-Hodgkin lymphoma (NHL) is one of the most common cancer types. Deregulated signaling pathways can trigger certain NHL subtypes, including Diffuse...

    Abas Sezer, Lejla Mahmutović, Betül Akçeşme in Medical Oncology

    Article 28 December 2023
    

18. Digital spatial profiling of CD4⁺ T cells in classic Hodgkin lymphoma

    Classic Hodgkin lymphoma (CHL) harbors a small number of Hodgkin-Reed-Sternberg (HRS) cells scattered among numerous lymphocytes. HRS cells are...

    Mai Takeuchi, Hiroaki Miyoshi, ... Koichi Ohshima in Virchows Archiv

    Article 04 June 2023
    

19. The role of IgG4-positive plasma cell population in classic Hodgkin lymphoma

    The effect of IgG4, which constitutes the least of the IgG subclasses, on the pathogenesis and prognosis of lymphoma or solid tumors is one of the...

    Beril Guler, Busra Cosanay Tekden, ... Irmak Sinal in Journal of Hematopathology

    Article 30 August 2023
    

20. Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma

    Anaplastic large cell lymphoma (ALCL) and classical Hodgkin lymphoma (HL) share a similar cytological and high surface expression of CD30, and novel...

    Wei Wei, Zhihui Song, ... Yibin Yang in Leukemia

    Article 01 December 2022